This is the authors' abstract. We don't add key points for this paper.
The regulatory circuits dictating CD8 + T cell responsiveness versus exhaustion during anti-tumor immunity are incompletely understood. Here we report that tumor-infiltrating antigen-specific PD-1 + TCF-1 − CD8 + T cells express the immunosuppressive cytokine Fgl2. Conditional deletion of Fgl2 specifically in mouse antigen-specific CD8 + T cells prolongs CD8 + T cell persistence, suppresses phenotypic and transcriptomic signatures of T cell exhaustion, and improves control of the tumor. In a mouse model of chronic viral infection, PD-1 + CD8 + T cell-derived Fgl2 also negatively regulates virus-specific T cell responses. In humans, CD8 + T cell-derived Fgl2 is associated with poorer survival in patients with melanoma. Mechanistically, the dampened responsiveness of WT Fgl2 -expressing CD8 + T cells, when compared to Fgl2 -deficient CD8 + T cells, is underpinned by the cell-intrinsic interaction of Fgl2 with CD8 + T cell-expressed FcγRIIB and concomitant caspase 3/7-mediated apoptosis. Our results thus illuminate a cell-autonomous regulatory axis by which PD-1 + CD8 + T cells both express the receptor and secrete its ligand in order to mediate suppression of anti-tumor and anti-viral immunity.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bennion et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: